Infliximab biosimilars to launch in the UK as innovator product reaches patent expiryNapp Pharmaceuticals and Hospira will both launch biosimilars of Janssen Biologic’s Remicade in the UK after its patent expires on 24 February 2015.…
FDA plays catch-up with Europe as it moves towards first biosimilar approval The US Food and Drug Administration (FDA)’s oncologic drugs advisory committee has given the green light to Sandoz’s EP2006, a biosimilar version of filgrastim.…
Forces driving the evolution of biologics into biosimilars and biobetters As demand for biologics increases, manufacturers are devising strategies to maximise their returns on investment and benefit patients.…
